Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel (Q37862646)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

author name string

Manfred Kaufmann

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Lajos Pusztai

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Biedenkopf Expert Panel Members

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

29 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1575-1582

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Identification of high risk breast-cancer patients by gene expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Standard operating procedure for the collection of fresh frozen tissue samples.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Recommendations for collection and handling of specimens from group breast cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Systematic review: gene expression profiling assays in early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Randomized clinical trials with biomarkers: design issues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Proficiency testing of immunohistochemical biomarker assays in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

21 January 2018

Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25660

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25660

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

release_a256afkcgvecje2ysrqmty36wq

1 reference

https://api.fatcat.wiki/v0/release/a256afkcgvecje2ysrqmty36wq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37862646&oldid=2088597088"